Suppr超能文献

终末期肾病患者行肾移植时,血管扩张剂应激心肌灌注成像中心率反应的预后价值。

The prognostic value of heart rate response during vasodilator stress myocardial perfusion imaging in patients with end-stage renal disease undergoing renal transplantation.

机构信息

Division of Cardiovascular Medicine, Clemenceau Medical Center, Beirut, Lebanon.

Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.

出版信息

J Nucl Cardiol. 2019 Jun;26(3):814-822. doi: 10.1007/s12350-017-1061-2. Epub 2017 Sep 18.

Abstract

BACKGROUND

In asymptomatic end-stage renal disease (ESRD) patients undergoing vasodilator stress myocardial perfusion imaging (MPI) prior to renal transplantation (RT), the impact of pre-transplant heart rate response (HRR) to vasodilator stress on post-RT outcomes is unknown.

METHODS

We analyzed a retrospective cohort of asymptomatic patients with ESRD who underwent a vasodilator stress SPECT-MPI and subsequently received RT. Blunted HRR was defined as HRR <28% for regadenoson stress and <20% for adenosine stress. The primary endpoint was major adverse cardiac events (MACE), defined as cardiac death or myocardial infarction. Clinical risk was assessed using the sum of risk factors set forth by the AHA/ACCF consensus statement on the assessment of RT candidates.

RESULTS

Among 352 subjects, 140 had an abnormal pre-transplant HRR. During a mean follow-up of 3.2 ± 2.0 years, 85 (24%) MACEs were observed. Blunted HRR was associated with increased MACE risk (hazard ratio 1.72; 95% confidence interval 1.12-2.63, P = 0.013), and remained significant after adjustment for gender, sum of AHA/ACCF risk factors, summed stress score, baseline heart rate, and β-blocker use. HRR was predictive of MACE in patients with normal MPI and irrespective of clinical risk. Blunted HRR was associated with a significant increase in post-operative (30-day) MACE risk (17.9% vs 8.5%; P = 0.009).

CONCLUSION

In asymptomatic ESRD patients being evaluated for RT, a blunted pre-transplant HRR was predictive of post-RT MACE. HRR may be a valuable tool in the risk assessment of RT candidates.

摘要

背景

在接受肾移植(RT)前进行血管扩张剂应激心肌灌注成像(MPI)的无症状终末期肾病(ESRD)患者中,移植前心率反应(HRR)对 RT 后结局的影响尚不清楚。

方法

我们分析了回顾性队列研究中接受血管扩张剂 SPECT-MPI 检查且随后接受 RT 的无症状 ESRD 患者。HRR 减弱定义为使用雷苷酸或腺苷进行血管扩张剂应激时 HRR<28%或<20%。主要心脏不良事件(MACE)是指心脏死亡或心肌梗死。临床风险采用美国心脏协会/美国心脏病学会基金会共识声明中规定的 RT 候选者评估的危险因素总和来评估。

结果

在 352 例患者中,有 140 例患者移植前 HRR 异常。在平均 3.2±2.0 年的随访期间,观察到 85 例(24%)MACE。HRR 减弱与 MACE 风险增加相关(风险比 1.72;95%置信区间 1.12-2.63,P=0.013),且在调整性别、美国心脏协会/美国心脏病学会基金会危险因素总和、总和应激评分、基线心率和β受体阻滞剂使用后仍有意义。HRR 可预测 MPI 正常患者的 MACE,且与临床风险无关。HRR 减弱与术后(30 天)MACE 风险显著增加相关(17.9%比 8.5%;P=0.009)。

结论

在接受 RT 评估的无症状 ESRD 患者中,移植前 HRR 减弱可预测 RT 后 MACE。HRR 可能是 RT 候选者风险评估的有用工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验